Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO)

Alimentary Pharmacology and Therapeutics

Volumn 45, Issue 3, 2017, Pages 468-475

  Buti, M ^a   Calleja, J L ^b   Lens, S ^c   Diago, M ^d   Ortega, E ^e   Crespo, J ^f   Planas, R ^g   Romero Gomez M ^h   Rodriguez F G ⁱ   Pascasio, J M ^j   Fevery, B ^k   Kurland, D ^l   Corbett, C ^k   Kalmeijer, R ^l   Jessner, W ^k  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Quiron Quantification Group   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h HOSPITAL UNIVERSITARIO DE VALME   (Spain)

ⁱ HOSPITAL RAMÓN Y CAJAL   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^k JANSSEN RESEARCH FOUNDATION   (Belgium)

^l JANSSEN RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TRIACYLGLYCEROL LIPASE; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; CATARRH; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HEADACHE; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HYPERKALEMIA; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; LIVER CIRRHOSIS; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PANCREATITIS; PHASE 3 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; RASH; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VIRUS LOAD; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER NEOPLASMS; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MIDDLE AGED; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 85006262160     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13883     Document Type: Article

References (30)

1. Wilder JM, Muir AJ. Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes. Ther Adv Chronic Dis 2015; 6: 314–27.
2. World Health Organization. Hepatitis C, 2015. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/ (accessed 29 June 2016).
3. Fagiuoli S, Ravasio R, Lucà MG, et al. Management of hepatitis C infection before and after liver transplantation. World J Gastroenterol 2015; 21: 4447–56.
4. Vidal LL, Soares MA, Santos AF. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naive subjects. J Viral Hepatol 2016; 23: 840–9.
5. Kamal SM, Nasser IA. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 2008; 47: 1371–83.
6. Kamal SM. Hepatitis C virus genotype 4 therapy: progress and challenges. Liver Int 2011; 31(Suppl. 1): 45–52.
7. Wantuck JM, Ahmed A, Nguyen MH. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther 2014; 39: 137–47.
8. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932–54.
9. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63: 199–236.
10. Moreno C, Hezode C, Marcellin P, et al. Efficacy and safety of simeprevir with PegIFN/ribavirin in naive or experienced patients infected with chronic HCV genotype 4. J Hepatol 2015; 62: 1047–55.
11. Gilead. SOVALDI Highlights of Prescribing Information. 2015. Available at: http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf (accessed 23 June 2016).
12. Kwo P, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in HCV genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology 2016; 64: 370–80.
13. Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology 2016; 64: 360–9.
14. Asselah T, De Muynck S, Broët P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56: 527–32.
15. El Raziky M, Gamil M, Hammad R, et al. Treatment of hepatitis C genotype 4 patients with simeprevir and sofosbuvir: results from a Phase IIa, partially randomized, open-label trial conducted in Egypt (OSIRIS). Poster 1163 presented at the American Association for the Study of Liver Disease (AASLD), San Francisco, CA, USA, 13–17 November 2015. Abstract. Available at: http://liverlearning.aasld.org/aasld/2015/thelivermeeting/110407/maissa.el.raziky.treatment.of.hepatitis.c.genotype.4.patients.with.simeprevir.html (accessed 21 November 2016).
16. Esmat G, Eldeen HG, El Kassas M, et al. Sofosbuvir plus simeprevir in treatment-naive and treatment-experienced Egyptian patients with hepatitis C virus infection: a real life experience. J Hepatol 2016; 64: abs SAT-160.
17. Derbala M, Alkaabi S, Sultan K, et al. 12 W of sofosbuvir/simeprevir in genotypes 1 and 4 in HCV, cirrhotic patients: Qatar experience. Hepatol Int 2016; 10 (Suppl. 1): abs O–022.
18. Moreno C, Lasser L, Delwaide J, et al. Sofosbuvir in combination with simeprevir +/- ribavirin in genotype 4 hepatitis C patients with advanced fibrosis or cirrhosis: real-life experience from Belgium. Hepatology 2015; 62 (Suppl. S1): abs 1091.
19. Abergel A, Loustaud-Ratti V, Metivier S, et al. Ledipasvir/Sofosbuvir for the treatment of patients with chronic genotype 4 or 5 HCV infection. Oral presentation presented at the 50th Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria, 22–26 April 2015. Available at: http://natap.org/2015/EASL/EASL_80.htm (accessed 21 November 2016).
20. Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016; 16: 685–97.
21. Hézode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015; 385: 2502–9.
22. Asselah T, Hézode C, Qaqish RB, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. Lancet Gastroenterol Hepatol 2016; 1: 25–35.
23. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis c virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015; 163: 1–13.
24. Kwo P, Gane E, Peng CY, et al. Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 or 16 weeks in patients with HCV G1, G4 or G6 infection who previously failed peginterferon/RBV: C-EDGE treatment-experienced. Poster presented at the European Association for the Study of the Liver, Vienna, Austria, 22–26 April 2015. Available at: http://www.natap.org/2015/EASL/EASL_04.htm (accessed 21 November 2016).
25. MajuMD.ar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther 2016; 43: 1276–92.
26. Banerjee D, Reddy KR. Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther 2016; 43: 674–96.
27. Younossi ZM, Stepanova M, Henry L, Nader F, Hunt S. An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. Am J Gastroenterol 2016; 111: 808–16.
28. Mishra P, Murray J, Birnkrant D. Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: scientific and regulatory approaches to clinical trial designs. Hepatology 2015; 62: 1298–303.
29. U.S.Food and Drug Administration. Guidance for industry: adaptive design clinical trials for drugs and biologics. 2010. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf (accessed 7 June 2016).
30. European Medicines Agency. General considerations for clinical trials. 1998. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002877.pdf (accessed 7 June 2016).